Skip to content

US · FLNA · BIOTECHNOLOGY

Filana Therapeutics, Inc. (FLNA) intrinsic value and stock valuation

$0.64as of 2026-11-21 · Mkt cap 46.37M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Filana Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values FLNA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FLNA’s statements →

Filana Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Austin, TX 78731 filanatx.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-90.97M
20212025
Free cash flow
-$-32.83M
20252025
Total equity
$74.4M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-95.39M-$-141.45M-$-105.96M-$-80.02M-$-32.87M
Net income-$-90.97M-$-24.34M-$-97.22M-$-76.25M-$-32.38M
EPSd-$-1.88M-$-5.22K-$-2.32M-$-1.9M-$-821.62K
Operating cash flow-$-32.25M————
Capital expenditure-$-580K————
Free cash flow-$-32.83M————
Total assets$118.4M————
Total debt$0.00————
Net debt-$-95.5M————
Total equity$74.4M————
Cash and short-term investments$95.5M————
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$940K$0.00$0.00$0.00$0.00
Gross profit-$-940K$0.00$0.00$0.00$0.00
Research and development expenses$26.6M$69.6M$89.4M$68M$24.8M
Selling, general and administrative expenses$67.9M$71.8M$16.5M$12M$8.05M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$94.5M$141.5M$106M$80M$32.9M
Cost and expenses$95.4M$141.5M$106M$80M$32.9M
Interest income$4.62M$8.51M$7.83M$2.78M$50K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$940K$1.13M$1.53M$1.3M$530K
Ebitda-$-90.04M-$-141.15M-$-105.8M-$-80.18M-$-31.85M
Operating income-$-95.39M-$-141.45M-$-105.96M-$-80.02M-$-32.87M
Total other income/expenses, net$4.42M$117.1M$8.74M$3.77M$480K
Income before tax-$-90.97M-$-24.34M-$-97.22M-$-76.25M-$-32.38M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-90.97M-$-24.34M-$-97.22M-$-76.25M-$-32.38M
Weighted average shares outstanding$48.3M$46.3M$41.9M$40.2M$39.4M
Weighted average diluted shares outstanding$48.3M$4.66B$41.9M$40.2M$39.4M
Balance sheet
2025
Cash and short-term investments$95.5M
Net receivables$120K
Inventory$0.00
Total current assets$97.7M
Property, plant and equipment, net$20.7M
Goodwill and intangible assets$0.00
Long-term investments$0.00
Total non-current assets$20.7M
Total assets$118.4M
Accounts payable$6.4M
Short-term debt$0.00
Deferred revenue$0.00
Total current liabilities$43.8M
Long-term debt$0.00
Deferred revenue, non-current$0.00
Total non-current liabilities$120K
Capital lease obligations$0.00
Total liabilities$44M
Common stock$50K
Retained earnings-$-496.08M
Accumulated other comprehensive income (loss)$0.00
Total equity$74.4M
Total investments$0.00
Total debt$0.00
Net debt-$-95.5M
Cash flow statement
2025
Net income-$-90.97M
Depreciation and amortization$940K
Stock-based compensation$0.00
Change in working capital$38.2M
Accounts receivable$0.00
Inventory$0.00
Accounts payable$34M
Net cash provided by operating activities-$-32.25M
Investments in property, plant and equipment-$-580K
Acquisitions, net$0.00
Net cash used for investing activities-$-580K
Common stock issued-$-240K
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities-$-240K
Net change in cash-$-33.07M
Cash at end of period$95.5M
Operating cash flow-$-32.25M
Capital expenditure-$-580K
Free cash flow-$-32.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Filana Therapeutics, Inc.

        Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

        CEO
        Richard Jon Barry
        Employees
        19
        Beta
        -0.74

        Explore

        Frequently asked questions

        What is the intrinsic value of Filana Therapeutics, Inc. (FLNA)?

        InvestorsCraft does not currently publish an intrinsic value for FLNA. How the IC value is calculated.

        Is FLNA undervalued?

        InvestorsCraft does not publish an undervaluation signal for FLNA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.